Yasuyuki Kakihana - Profile and Journalist Details

Beats

Content

Total articles 3

• Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

  By Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima| The Lancet Verified Background Tachycardia and atrial fibrillation frequently occur in patients being treated for sepsis or septic shock and have a poor prognosis. Treatments for tachyarrhythmias are often ineffective or contraindicated in this setting. We aimed to investigate the efficacy and safety of landiolol, an ultra-short-acting β-blocker, for treating sepsis-related tachyarrhythmias. Methods We did a multicentre, open-label, randomised controlled trial at 54 hospitals in Japan.

  By Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima · The Lancet

  Mar. 31, 2020

• Is early goal-directed therapy associated with a higher risk of adverse events?

  By Ahmad Sabry Saleh, Yasuyuki Kakihana| Journal of Intensive Care Verified Yasuyuki Kakihana2, Asako Matsushima3 and Osamu Nishida4 (2) Department of Emergency and Intensive Care Medicine-Kagoshima, University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (3) Department of Advancing Acute Medicine, Nagoya University Graduate School of Medical Sciences, Nagoya, Japan (4) Department of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine-Toyoake, Aichi, Japan We read the letter to the editor from Dr. Saleh with...

  By Ahmad Sabry Saleh, Yasuyuki Kakihana · Journal of Intensive Care

  Nov. 27, 2018

• Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

  By Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima| The Lancet Verified Background Tachycardia and atrial fibrillation frequently occur in patients being treated for sepsis or septic shock and have a poor prognosis. Treatments for tachyarrhythmias are often ineffective or contraindicated in this setting. We aimed to investigate the efficacy and safety of landiolol, an ultra-short-acting β-blocker, for treating sepsis-related tachyarrhythmias. Methods We did a multicentre, open-label, randomised controlled trial at 54 hospitals in Japan.

  By Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima · The Lancet

  Mar. 31, 2020

As seen in

Company Info